ArticleSaudi medical journal2026
Immunoinformatic based Development of a Multi-Epitope Precision Vaccine Targeting Glycoprotein and RdRp of Oropouche Virus:
Article in Saudi medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To design high immunogenic vaccine against the Oropouche virus (OROV). The OROV is a neglected arbovirus endemic to Central and South America, causes oropouche fever, which can progress to severe complications such as meningitis and hemorrhagic symptoms. Methods: We utilized immunoinformatic and molecular dynamic simulation approaches to design highly immunogenic vaccines against OROV. This observational study, carried out between January and August 2024 in Saudi Arabia. As it involves an in-silico method, ethical consent was not required. Results: Docking analysis confirmed the stable interaction of the designed vaccines with human toll-like receptors (TLR)-3, producing binding scores of -300.78, -306.19, and -288.60 kcal/mol for the glycoprotein, ribonucleic acid (RNA)-dependent RNA polymerase (RdRp), and combined vaccine, respectively. Furthermore, molecular dynamics simulations supported the stability of the vaccine-TLR-3 complexes. The calculated total binding free energies were -107.44 kcal/mol for glycoprotein-TLR-3, -33.64 kcal/mol for RdRp -TLR-3, and -78.62 kcal/mol for the combined vaccine-TLR-3 interaction. The computed codon adaptation index (CAI) values for the vaccines were notably 0.96, with guanine-cytosine (GC) content ranging between 65% and 66%, suggesting strong potential for high expression in the pET28a+ vector. The analysis of immune simulation showed rapid antigen clearance, accompanied by sustained and elevated immunoglobulin (Ig)M and IgG responses. Conclusion: This study presents a potent and secure vaccine candidate to combat the emerging Oropouche virus infection, which requires further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.